Skip to content
← Full study record

NCT00052910 · BASELINE

Baseline characteristics

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer · Source last updated 2020-05-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      280
    2. group Id
      BG001
      value
      266
    3. group Id
      BG002
      value
      546
    units
    Participants
groups
  1. description
    Patients receive leucovorin calcium (LV) IV (20 mg/m\^2 per day) and fluorouracil (5-FU) IV (425 mg/m\^2 per day) on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
    id
    BG000
    title
    Arm I (5-FU/LV)
  2. description
    Patients receive epirubicin IV (50 mg/m\^2) over 3-15 minutes and cisplatin IV (60 mg/m\^2) over 1 hour on day 1 and 5-FU IV (200 mg/m\^2 per day) continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
    id
    BG001
    title
    Arm II (ECF)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          23
          upper Limit
          81
          value
          59
        2. group Id
          BG001
          lower Limit
          29
          upper Limit
          83
          value
          58
        3. group Id
          BG002
          lower Limit
          23
          upper Limit
          83
          value
          58.6
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          87
        2. group Id
          BG001
          value
          88
        3. group Id
          BG002
          value
          175
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          193
        2. group Id
          BG001
          value
          178
        3. group Id
          BG002
          value
          371
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
        2. group Id
          BG001
          value
          17
        3. group Id
          BG002
          value
          38
      title
      Canada
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          259
        2. group Id
          BG001
          value
          249
        3. group Id
          BG002
          value
          508
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      280
    2. group Id
      BG001
      value
      266
    3. group Id
      BG002
      value
      546
    units
    Participants
groups
  1. description
    Patients receive leucovorin calcium (LV) IV (20 mg/m\^2 per day) and fluorouracil (5-FU) IV (425 mg/m\^2 per day) on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
    id
    BG000
    title
    Arm I (5-FU/LV)
  2. description
    Patients receive epirubicin IV (50 mg/m\^2) over 3-15 minutes and cisplatin IV (60 mg/m\^2) over 1 hour on day 1 and 5-FU IV (200 mg/m\^2 per day) continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
    id
    BG001
    title
    Arm II (ECF)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          23
          upper Limit
          81
          value
          59
        2. group Id
          BG001
          lower Limit
          29
          upper Limit
          83
          value
          58
        3. group Id
          BG002
          lower Limit
          23
          upper Limit
          83
          value
          58.6
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          87
        2. group Id
          BG001
          value
          88
        3. group Id
          BG002
          value
          175
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          193
        2. group Id
          BG001
          value
          178
        3. group Id
          BG002
          value
          371
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
        2. group Id
          BG001
          value
          17
        3. group Id
          BG002
          value
          38
      title
      Canada
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          259
        2. group Id
          BG001
          value
          249
        3. group Id
          BG002
          value
          508
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice